目的 基于多巴胺衍生物的粘附性，構(gòu)建表面改性的紫杉醇（PTX）納米粒，連接阿倫磷酸鈉（ALN），對(duì)構(gòu)建的新型納米粒進(jìn)行表征并考察其對(duì)鼠源性乳腺癌4T1細(xì)胞的毒性作用。方法 采用溶劑沉淀法制備PTX納米粒，將納米粒放置于0.5 mg/mL的鹽酸多巴胺Tris緩沖鹽溶液中，在表面形成聚合多巴胺（PDA），隨后與親骨性藥物ALN結(jié)合，得到新型PTX-PEG₅₀₀₀PCL₁₀₀₀-PDA-ALN納米粒。ZS型電位儀測(cè)定納米粒的粒徑、粒度分布和表面電位；透射電鏡觀察形態(tài)；考察其在不同介質(zhì)中的穩(wěn)定性、溶血性；考察ALN用量及鈣離子存在條件對(duì)新型納米粒吸附羥基磷灰石[（Ca₁₀PO₄）₆（OH）₂，HA]的影響；研究其體外抗4T1乳腺癌細(xì)胞活性。結(jié)果 成功制得PTX-PEG₅₀₀₀PCL₁₀₀₀-PDA-ALN納米粒，棒狀，粒徑為（178.5±2.3）nm，分散指數(shù)（PDI）值為0.213±0.06，Zeta電位為（20.12±2.45）mV；在5%葡萄糖、0.9%生理鹽水、血漿中基本穩(wěn)定；無(wú)溶血現(xiàn)象；隨著ALN用量增加，新型納米粒對(duì)HA吸附率增大，可達(dá)48.63%，游離鈣離子降低其對(duì)HA的吸附能力；MTT結(jié)果顯示，其對(duì)4T1乳腺癌細(xì)胞發(fā)揮顯著抑制作用。結(jié)論 制備的PTX-PEG₅₀₀₀PCL₁₀₀₀-PDA-ALN納米粒粒度分布均勻、穩(wěn)定性良好、不溶血；通過(guò)ALN與HA上的鈣離子相結(jié)合，親骨性良好；對(duì)4T1細(xì)胞發(fā)揮毒性作用。

Objective Based on the adhesion of dopamine derivatives, the surface modified paclitaxel (PTX) nanoparticles were constructed and connected with Allen sodium phosphate (ALN). The new nanoparticles were characterized and the toxic effects on 4T1 cells were observed. Methods PTX nanoparticles were prepared by solvent precipitation method. The nanoparticles were placed in 0.5 mg/mL dopamine hydrochloride Tris buffer salt solution to form polymeric dopamine (PDA) on the surface, and then combined with the pro osseous drug ALN to obtain novel PTX-PEG_{5 000}PCL_{1 000}-PDA-ALN nanoparticles. Dynamic light scattering and transmission electron microscopy were used to investigate the size and morphology of the new nanoparticle. The stability and hemolysis in different medium were studied. Investigated the effect of ALN dosage and calcium ion condition on the adsorption of novel nanoparticles on hydroxyapatite (Ca₁₀PO₄)₆(OH)₂, HA] and studied its antitumor activity on 4T1 breast cancer in vitro. Results Successfully prepared PTX-PEG_{5 000}PCL_{1 000}-PDA-ALN nanoparticles, rod diameter (178.5 ±2.3) nm, Zeta potential (-20.12 ±2.45) mV, basically stable in 5% glucose, 0.9% saline and plasma, and no hemolysis. In vitro experiment results showed that, with the increase of ALN dosage, the adsorption rate of the new nanoparticles on HA increased, up to 48.63%, and the free calcium ions reduced the adsorption capacity; In vitro cytotoxicity assay (MTT) results showed that, PTX-PEG_{5 000}PCL_{1 000}-PDA-ALN nanoparticles had a significant inhibitory effect on 4T1 breast cancer cells. Conclusion The prepared PTX-PEG_{5 000}PCL₁₀₀₀-PDA-ALN nanoparticles have uniform particle size distribution, good stability and did not cause hemolysis; Moreover, they have good affinity to bone through ALN and calcium ions on HA, and play a toxic role in 4T1 cells.